A new subtype classification of ischemic stroke was developed to reflect recent therapeutic strategies as well as evolving concepts of stroke definitions and mechanisms. In 200 consecutive patients with acute ischemic stroke, the inter-rater reliability and proportion of subtypes of the new classification system were assessed and compared with those of the Trial of ORG 10172 in the Acute Stroke Treatment (TOAST) classification. The most frequent subtype of the new classification was atherothrombosis (n = 80, 40%), followed by stroke of undetermined etiology (n = 54, 27%), small artery disease (n = 33, 16.5%), cardioembolism (n = 26, 13%), and stroke of other determined etiology (n = 7, 3.5%). Three raters agreed to the stroke subtype diagnosis in 165 out of 200 cases and the overall ĸ value was excellent (ĸ = 0.82). The new classification system for brain infarction was easy to use and had high inter-rater reliability.

Keywords:
Cerebral infarction, Ischemic stroke classification, Stroke subtype diagnosis
1.
Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ: An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005;58:688–697.
2.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35–41.
3.
Goldstein LB, Jones MR, Matchar DB, Edwards LJ, Hoff J, Chilukuri V, Armstrong SB, Horner RD: Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. Stroke 2001;32:1091–1098.
4.
Landau WM, Nassief A: Editorial comment – time to burn the TOAST. Stroke 2005;36:902–904.
5.
Albers GW, Caplan LR, Easton JD, Fayad PB, Mohr JP, Saver JL, Sherman DG, the TIA Working Group: Transient ischemic attack – proposal for a new definition. N Engl J Med 2002;347:1713–1716.
6.
Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG: Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–1316.
7.
Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP Jr, Jackson CM, Pullicino P, the Warfarin-Aspirin Recurrent Stroke Study Group: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444–1451.
8.
North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325:445–453.
9.
European Carotid Surgery Trialists’ Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–1387.
10.
CAVATAS Investigators: Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet 2001;357:1729–1737.
11.
The SSYLVIA Study Investigators: Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388–1392.
12.
Gallego J, Martinez-Vila E: Asymptomatic cerebrovascular disease and systemic diagnosis in stroke, atherothrombosis as a disease of the vascular tree. Cerebrovasc Dis 2005;20(suppl 2):1–10.
13.
Drouet L: Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002;13:1–6.
14.
van Wijk I, Kappelle L, van Gijn J, Koudstaal P, Franke C, Vermeulen M, Gorter J, Algra A, for the LiLAC study group: Long-term survival and vascular event risk after transient ischemic attack or minor ischemic stroke: a cohort study. Lancet 2005;365:2098–2104.
15.
Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005;366:1773–1783.
16.
Kannel WB, Wolf PA, Verter J: Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 1983;250:2942–2946.
17.
Hankey GJ: Vascular disease of the heart, brain and limbs: new insights into a looming epidemic. Lancet 2005;366:1753–1754.
18.
Amarenco P, Lavallee P, Touboul PJ: Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004;3:271–278.
19.
Bonita R, Stewart A, Beaglehole R: International trends in stroke mortality: 1970–1985. Stroke 1990;21:989–992.
20.
Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul PJ, Bousser MG: Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994;331:1474–1479.
21.
Lee BI, Nam HS, Heo JH, Kim DI: Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis 2001;12:145–151.
22.
Fleiss JL: Measuring nominal scale agreement among many raters. Psychol Bull 1971;76:378–382.
23.
Kidwell CS, Alger JR, Di Salle F, Starkman S, Villablanca P, Bentson J, Saver JL: Diffusion MRI in patients with transient ischemic attacks. Stroke 1999;30:1174–1180.
24.
Lammie GA, Sandercock PAG, Dennis MS: Recently occluded intracranial and extracranial carotid arteries: relevance of the unstable atherosclerotic plaque. Stroke 1999;30:1319–1325.
25.
Bang OY, Lee PH, Joo SY, Lee JS, Joo IS, Huh K: Frequency and mechanisms of stroke recurrence after cryptogenic stroke. Ann Neurol 2003;54:227–234.
26.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339.
27.
Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke. The French Study of Aortic Plaques in Stroke Group. N Engl J Med 1996;334:1216–1221.
28.
Baumgartner RW, Sidler C, Mosso M, Georgiadis D: Ischemic lacunar stroke in patients with and without potential mechanism other than small-artery disease. Stroke 2003;34:653–659.
29.
Bogousslavsky J, Van Melle G, Regli F: The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988;19:1083–1092.
30.
Jackson C, Sudlow C: Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke 2005;36:891–901.
31.
Norrving B: Long-term prognosis after lacunar infarction. Lancet Neurol 2003;2:238–245.
32.
Moncayo J, Devuyst G, Melle GV, Bogousslavsky J: Coexisting causes of ischemic stroke. Arch Neurol 2000;57:1139–1144.
33.
Jung DK, Devuyst G, Maeder P, Bogousslavsky J: Atrial fibrillation with small subcortical infarcts. J Neurol Neurosurg Psychiatry 2001;70:344–349.
34.
Inzitari D, Eliasziw M, Sharpe BL, Fox AJ, Barnett HJM: Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. Neurology 2000;54:660–666.
35.
Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF: Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. The TOAST Investigators. Neurology 1993;43:1021–1027.
© 2007 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.